Compare CXDO & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | PEPG |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 207.1M |
| IPO Year | 1999 | 2022 |
| Metric | CXDO | PEPG |
|---|---|---|
| Price | $6.26 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $9.20 | ★ $11.17 |
| AVG Volume (30 Days) | 334.4K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | 25.61 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $68,167,000.00 | N/A |
| Revenue This Year | $45.26 | N/A |
| Revenue Next Year | $13.31 | N/A |
| P/E Ratio | $128.40 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $5.55 | $1.17 |
| 52 Week High | $11.23 | $7.80 |
| Indicator | CXDO | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.33 | 59.32 |
| Support Level | $6.18 | $1.47 |
| Resistance Level | $6.76 | $3.14 |
| Average True Range (ATR) | 0.21 | 0.20 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 43.33 | 27.27 |
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.